Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis

Editorial Material Oncology

What is the role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma?

Takafumi Yanagisawa et al.

EXPERT REVIEW OF ANTICANCER THERAPY (2023)

Letter Medicine, General & Internal

Comparison of Anti-Programmed Cell Death Ligand 1 Therapy Combinations vs Sunitinib for Metastatic Renal Cell Carcinoma: A Meta-analysis

Brigida Anna Maiorano et al.

Summary: This meta-analysis examines the relationship between the use of combined anti-PD-L1 agents and survival and response rate in patients with metastatic renal cell carcinoma.

JAMA NETWORK OPEN (2023)

Add to Collection

Article Urology & Nephrology

Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma

Takafumi Yanagisawa et al.

European Urology Focus (2023)

Add to Collection

Article Cell Biology

Beyond the Complement Cascade: Insights into Systemic Immunosenescence and Inflammaging in Age-Related Macular Degeneration and Current Barriers to Treatment

Adnan H. Khan et al.

Cells (2023)

Add to Collection

Review Urology & Nephrology

Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis

Takafumi Yanagisawa et al.

Summary: The purpose of this study was to analyze and summarize the efficacy of immune checkpoint inhibitor (ICI) alone or in combination therapy for renal cell carcinoma (RCC) and urothelial carcinoma (UC) stratified by sex. The results showed that ICI-based combination therapies significantly improved overall survival (OS) in first-line treatment of metastatic RCC and UC patients, regardless of sex. However, gender differences were observed in the efficacy of adjuvant ICI monotherapy.

WORLD JOURNAL OF UROLOGY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Immunosenescence: molecular mechanisms and diseases

Zaoqu Liu et al.

Summary: Aging is associated with immune dysfunction, chronic inflammation (inflammaging), and increased risk of age-related diseases. Senescent T cells and inflammaging are major drivers of immunosenescence. Investigating the role of immunosenescence in cancer and other age-related diseases is necessary.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

Add to Collection

Review Urology & Nephrology

Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials

Alessandro Rizzo et al.

Summary: This study conducted a meta-analysis to explore the predictive value of immune checkpoint inhibitors (ICI) plus tyrosine kinase inhibitors (TKI) in the treatment of metastatic renal cell carcinoma (mRCC) patients. The results showed that the combination therapy had significant survival benefits in different clinicopathological subgroups.

EUROPEAN UROLOGY FOCUS (2022)

Add to Collection

Article Oncology

Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma

Wataru Fukuokaya et al.

Summary: This study suggests that continued use of pembrolizumab beyond progression may be beneficial in patients with metastatic UC, leading to a significantly longer overall survival.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Add to Collection

Review Oncology

New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis

Pasquale Lombardi et al.

Summary: This study conducted a systematic review and network meta-analysis of first-line immune-checkpoints inhibitors (ICI) based combinations in metastatic renal cell carcinoma (mRCC). The results showed that lenvatinib plus pembrolizumab had the highest probability to be the best treatment in terms of overall survival (OS) and progression-free survival (PFS). In sarcomatoid patients, nivolumab plus cabozantinib ranked highest in survival outcomes.

CANCER TREATMENT REVIEWS (2022)

Add to Collection

Review Urology & Nephrology

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update

Borje Ljungberg et al.

Summary: The European Association of Urology has prepared evidence-based guidelines for the management of RCC, which were updated in 2022 using a standardized methodology. The guidelines provide transparent and reliable evidence for the management of RCC, based on a thorough literature assessment and clinical practice recommendations.

EUROPEAN UROLOGY (2022)

Add to Collection

Article Oncology

Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101

Y. Tomita et al.

Summary: In patients with renal cell carcinoma, the combination of avelumab and axitinib as first-line treatment showed favorable efficacy across different age groups, including elderly patients. The safety profile remained consistent across the age groups.

ESMO OPEN (2022)

Add to Collection

Review Biochemistry & Molecular Biology

The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints

Paolo Giuffrida et al.

Summary: Hepatocellular carcinoma is a challenging malignancy with clinical and biological heterogeneity. The landscape of systemic therapies has changed with the advent of immune-checkpoint inhibitors. Proper clinical endpoints are needed to evaluate the treatment benefit.

BIOMEDICINES (2022)

Add to Collection

Article Oncology

The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression

C.M. Kim et al.

ESMO Open (2022)

Add to Collection

Article Oncology

Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis

Weiming Han et al.

Summary: This study aimed to investigate whether PFS can serve as a surrogate endpoint for OS in ESCC patients and characterize the prognostic factors and survival of these patients. The study found that three-year PFS may act as a potential surrogate endpoint for five-year OS, and TNM stage was considered a significant prognostic factor.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors

Hiroki Hata et al.

Summary: This study investigated the association between the occurrence of immune-related adverse events (irAEs) and overall survival (OS) and progression-free survival (PFS) in patients with non-small-cell lung cancer (NSCLC), gastric cancer (GC) and melanoma (MM) treated with immune checkpoint inhibitors (ICIs). The results showed that patients with irAEs tended to have better OS or PFS. Age, albumin, and smoking history were identified as significant risk factors for the development of irAEs.

CANCER CONTROL (2022)

Add to Collection

Article Oncology

The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations

Cho-Han Chiang et al.

Summary: Among Asians, the use of immune checkpoint inhibitors is associated with an increased risk of major adverse cardiovascular events, particularly ischemic stroke and pulmonary embolism. The risk of major adverse cardiovascular events is 60% higher in immune checkpoint inhibitor users, with an incidence rate ratio of 2.1 compared to non-users. Additionally, immune checkpoint inhibitors are independently associated with an increased risk of ischemic stroke and pulmonary embolism.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Urology & Nephrology

Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab

Wataru Fukuokaya et al.

Summary: iRECIST is more accurate in predicting overall survival of patients with metastatic urothelial carcinoma treated with pembrolizumab compared to RECIST. Multivariable Cox regression models showed that objective response and time to progression per iRECIST were significantly associated with all-cause mortality. Additionally, iRECIST showed enhanced predictability of overall survival and better net benefit gains on decision curve analysis compared to RECIST.

BJU INTERNATIONAL (2021)

Add to Collection

Review Oncology

Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis

Keiichiro Mori et al.

Summary: Based on the study findings, pembrolizumab plus axitinib may be the most effective first-line treatment for mRCC, while nivolumab plus ipilimumab has a favorable balance of efficacy and tolerability. These findings could aid in developing personalized treatment strategies and guiding future direct comparative trials.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Medicine, General & Internal

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert Motzer et al.

Summary: The study demonstrated that the combination of lenvatinib with pembrolizumab led to significantly longer progression-free survival and overall survival than sunitinib, while the combination of lenvatinib with everolimus showed longer progression-free survival but not overall survival compared to sunitinib. Adverse events were more frequent in patients receiving lenvatinib-based treatments.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial

Martin John Connor et al.

Summary: IP2-ATLANTA will explore the progression-free survival (PFS) outcomes with the addition of sequential multimodal local and metastasis-directed treatments compared with standard care alone.

BMJ OPEN (2021)

Add to Collection

Review Oncology

Efficacy of Anti-PD-1/PD-L1 Monotherapy or Combinational Therapy in Patients Aged 75 Years or Older: A Study-Level Meta-Analysis

Run-Cong Nie et al.

Summary: Recent meta-analysis compared the efficacy of anti-PD-1/PD-L1 agents in elderly (>= 75 years) and non-elderly (< 75 years) patients, showing that except for melanoma, elderly patients did not benefit from these agents in terms of survival. The study highlighted a significant difference in efficacy between elderly and non-elderly patients, underscoring the need for further exploration of drug toxicity profiles in the elderly population.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Urology & Nephrology

The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis

Keiichiro Mori et al.

Summary: In mRCC patients treated with ICIs, PD-L1-positive tumors are associated with higher ORRs and prolonged PFS. The status of PD-L1 may help identify mRCC patients most likely to benefit from ICI treatment.

EUROPEAN UROLOGY (2021)

Add to Collection

Review Oncology

First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis

Fahad Quhal et al.

Summary: The study performed indirect comparisons of first-line immune checkpoint inhibitor (ICI)-based combination therapies for metastatic renal cell carcinoma (mRCC), revealing the advantages and disadvantages of different therapeutic combinations. The findings suggest that combinations of ICIs and tyrosine kinase inhibitors (TKIs) may provide superior treatment options in the first-line setting, while ICI-ICI combinations could be optimal for tumors with increased PD-L1 expression.

EUROPEAN UROLOGY ONCOLOGY (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Rena Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy

Bingjie Zheng et al.

Summary: The study evaluated the radiological tumor response patterns based on iRECIST and RECIST 1.1 in metastatic clear-cell renal cell carcinoma patients treated with PD-1 inhibitors. It found that iRECIST criteria are more capable of capturing immune-related atypical responses during immunotherapy, while RECIST 1.1 may underestimate the benefit of PD-1 inhibitors. Pseudoprogression is not rare in these patients during PD-1 inhibitor therapy, indicating a limitation of the current strategy for immune response monitoring.

KOREAN JOURNAL OF RADIOLOGY (2021)

Add to Collection

Article Oncology